Going Global: Partnering and Investing in International Life Sciences

I will be presenting in an upcoming webinar:

Going Global

Partnering and Investing in International Life Sciences

Today, successful life sciences companies are feverishly evaluating international partnerships in search of places that are rapidly expanding. Some make the costly mistake of only using market size as the deciding factor, which is often misleading. Success in the global marketplace is driven by many factors. Overlooking these additional factors may be detrimental to your international goals.

During this webinar, you will:

  • Hear why a deep understanding of your potential partner’s innovation record is essential
  • Learn how to measure the true size and growth rate of a specific market
  • Understand why focus must center on individual countries rather than region
  • Discover how to identify and mitigate commercial risk abroad
  • Learn how to create a checklist for partnering and investing internationally
  • See how one company has used technology to securely and efficiently accomplish their international licensing goals

Go here to learn more about this complimentary webinar sponsored by MERRILL DATASITE®.

Date & Time

June 7, 2011
1:00PM EDT / 10:00AM PDT
90 Minutes

Add to Outlook Calendar Add to Outlook Calendar

Register

Speakers

Yali Friedman, PhD

Yali Friedman, PhD Founder

thinkBiotech

Yali Friedman, Ph.D., is Founder of thinkBiotech. His book, Building Biotechnology, is used as a course text in dozens of biotechnology programs. His other books include Best Practices in Biotechnology Education and Best Practices in Biotechnology Business Development. Dr. Friedman also has strong exposure to leading issues in international biotechnology. Dr. Friedman teaches biotechnology management at the NIH and regularly guest-lectures for other biotechnology education programs, and writes and speaks on diverse topics such as biotechnology entrepreneurship, strategies to cope with a lack of management talent and capital when developing companies outside of established hubs, and new paradigms in technology-based economic development.

Jim Weissman

Jim Weissman Vice President of Business Development

MannKind

As Vice President of Business Development for MannKind, Jim Weissman leads MannKind’s strategic alliance and licensing partnership efforts. He brings over 20 years of experience in general management, business development, and marketing in biotech and pharmaceuticals having worked in senior management positions at Pharmacia and Pfizer. Weissman served as the General Manager for Pharmacia Biotech UK & Ireland where he headed country operations including sales, marketing, customer support, and operations. He also served as the Director of Business Development for Pfizer Japan where he headed the New Product Planning, Licensing, and Corporate Strategic Planning Departments. Weissman received his B.S. in Chemistry from Bates College and has extensive international experience having lived and worked in Europe for 5 years and Japan for 11 years prior to returning to the USA in 2006.

David Yeary

David Yeary Moderator

Merrill Corporation

David Yeary is the Vice President of Sales-Life Sciences for Merrill’s DataSite. Most recently, Mr. Yeary worked at Morgan Lewis as Director, Business and Practice Development where he assisted and lead business development opportunities in Life Sciences, Technology, Clean Tech and Digital Media and Entertainment. He also worked with private equity, venture capital and investment banks to bridge between client and investor. Mr. Yeary gained his experience at Synarc, Celera, IMS, Agouron/Pfizer and Roche/Syntex in various business development, sales and marketing roles. He has and continues to work with numerous startups as an advisor for business development, commercialization and marketing and communication functions. Periodically he can be heard on the radio or speaking at Stanford discussing the challenges and opportunities for the new entrepreneur. He holds a BS and MBA in business from California State University, Fresno.

Originally Posted: biotechblog.com

2 Responses to Going Global: Partnering and Investing in International Life Sciences

  1. Vibharti June 2, 2011 at 3:29 am #

    Dr. Vibhav Garg is a leading career coach for the aspiring students and professionals in life sciences and pharma domain. Dr Garg, on one hand, has been working closely with various government agencies like DBT, DST, DIT, ICMR and on the other hand he has been interacting with various universities and organizations responsible for production and supply of quality professionals in these domains. He has been recognized as valuable resource in the mentioned domain and has been taken on board by leading industry body of India i.e. CII (Confederation of Indian Industry) to Head the Life Sciences & Pharma vertical. Dr Garg not only guide the aspirants for the fit and suitability of various career options, they might have but also mentor them proactively to enable them to reach the industry. As:
    CAREER COACH: motivates and guides students, professionals and career changers in their quest for professional fulfillment and success. His focus is on helping upcoming professionals and career changers face the challenges of this industry.

    CAREER COUNSELOR: specializes in highly personalized career management coaching. His
    HOLISTIC APPROACH takes you through 3 steps of Knowing, Branding, and Marketing Yourself for today’s job market. He works with motivated professionals individually and in groups to help them formulate a career path that will allow for the expression of their passions, values, skills and talents. His
    COMPREHENSIVE career assessment helps people find their BEST FIT by DEFINING, REFINING and PROMOTING their INDIVIDUAL BRAND EQUITY.

  2. Monex fraud July 21, 2011 at 9:54 am #

    In many FDA-regulated companies the marketing and business development departments have a quietly antagonistic relationship with their quality and regulatory affairs colleagues. While compliance is supposed to ensure that a safe efficacious and high-quality new product reaches the marketplace marketing and business development executives are left to grumble how are consumers much less partners and investors supposed to learn about and get excited about a new product if their work is so constricted?